Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced that the Onxeo shareholders are invited to attend the Company’s Combined Ordinary and Extraordinary General Meeting which will be held on Wednesday, May 16, 2018 at 10:00 am CEST at the Onxeo head office at 49 Boulevard du Général Martial Valin, 75015 Paris, France.
The official notice of the General Meeting was published in the French Republic’s Bulletin des Annonces Légales Obligatoires (i.e. the “Bulletin of Mandatory Legal Announcements”) on April 11, 2018 and includes the agenda, the draft resolutions, and information on attendance and voting procedures. Under the conditions set out by the current legislation, you can find the full notice, together with all other related documents, on the Onxeo website: http://www.onxeo.com/en/investisseurs/assemblee-generale/
The related documents are available to shareholders at the company’s head office and on the Company’s website. Shareholders may request to receive the documents by sending their request by post to Onxeo (Direction Financière – 49 boulevard du Général Martial Valin, 75015 Paris, France), or email (firstname.lastname@example.org).